MTATP6P13

Across TCGA pan-cancer cohorts, MTATP6P13 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated MTATP6P13 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher MTATP6P13 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTATP6P13 expression acts as an unfavorable survival marker, although some lineages such as BLCA and ESCA show a favorable association.

MESO, BLCA, and LGG are the cancer types where MTATP6P13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	III,IV	0.137	0.573	<.001	81	view →
BLCA	OS	Tertile	II,III,IV	0.888	0.694	.021	24	view →
LGG	OS	Tertile	All	0.523	0.891	<.001	18	view →
PRAD	OS	Tertile	All	0.956	0.997	.001	18	view →
READ	DFS	Tertile	All	0.232	0.729	.037	9	view →
PCPG	DFS	Tertile	All	0.607	0.941	.004	9	view →
LIHC	DFS	Tertile	III,IV	0.081	0.413	.048	9	view →
UVM	OS	Tertile	All	0.315	0.711	.049	9	view →
ESCA	OS	Tertile	III,IV	0.643	0.341	.028	8	view →
THCA	OS	Tertile	III,IV	0.920	0.980	.035	6	view →
OV	OS	Quartile	II,III,IV	0.896	0.822	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MTATP6P13–MESO (OS)

Open the MESO breakdown →